Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00238732|
Recruitment Status : Completed
First Posted : October 13, 2005
Last Update Posted : December 28, 2007
|Condition or disease||Intervention/treatment||Phase|
|Vaginal Atrophy||Drug: Bazedoxifene/Conjugated Estrogen||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||650 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||A Double-Blind, Randomized, Placebo-and Active-Controlled Efficacy and Safety Study of Bazedoxifene/Conjugated Estrogens Combinations for Treatment of Moderate to Severe Vulvar/Vaginal Atrophy in Postmenopausal Women|
|Study Start Date :||October 2005|
|Study Completion Date :||March 2007|
- Superficial cells (by cervical/vaginal cytologic smear) at screening, and weeks 4 and 12.
- Parabasal cells (by cervical/vaginal cytologic smear) at screening, and weeks 4 and 12.
- Vaginal pH at screening, and weeks 4 and 12.
- Most bothersome moderate or severe vulvar/vaginal atrophy sympton at screening, and weeks 4 and 12.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00238732
Show 63 Study Locations
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|